Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial
Patritumab Deruxtecan (HER3-DXd),一种靶向人表皮生长因子受体 3 的抗体药物偶联物,用于治疗既往接受过治疗的人表皮生长因子受体 3 表达转移性乳腺癌患者:一项多中心 I/II 期试验
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.23.00882
Krop, Ian E; Masuda, Norikazu; Mukohara, Toru; Takahashi, Shunji; Nakayama, Takahiro; Inoue, Kenichi; Iwata, Hiroji; Yamamoto, Yutaka; Alvarez, Ricardo H; Toyama, Tatsuya; Takahashi, Masato; Osaki, Akihiko; Saji, Shigehira; Sagara, Yasuaki; O'Shaughnessy, Joyce; Ohwada, Shoichi; Koyama, Kumiko; Inoue, Tatsuya; Li, Li; Patel, Parul; Mostillo, Joseph; Tanaka, Yoshimi; Sternberg, David W; Sellami, Dalila; Yonemori, Kan